<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527250</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-ASC41-I-CTP-02</org_study_id>
    <nct_id>NCT04527250</nct_id>
  </id_info>
  <brief_title>A Study of the Relative Bioavailability of ASC41 in Healthy Subjects</brief_title>
  <official_title>Comparison of the Pharmacokinetic Parameters of ASC41, a Randomized, Double-blind, Placebo-controlled in Healthy Subjects After Single and Multiple Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy&#xD;
      subjects after single and multiple oral dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and&#xD;
      pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind,&#xD;
      placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the&#xD;
      study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be&#xD;
      observed after repeated administration of ASC41 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety and tolerability of ASC41 in healthy volunteers</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Evaluation of the safety and tolerability of ASC41 in healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Peak Plasma Concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Time to reach the maximum plasma concentration after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Terminal-Phase Half-Life after single and multiple oral doses of ASC41 administered to Chinese healthy volunteers volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Apparent Systemic Clearance after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of ASC41</measure>
    <time_frame>On Day 1,2,3,4 after single doses and On Day 1,2,3,4 after multiple doses, respectively. The entire study will last up to 32 days.</time_frame>
    <description>Evaluate the Apparent Volume of Distribution after single and multiple oral dose of ASC41 administered to Chinese healthy volunteers.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental:1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 two tablets (10mg) single oral dose at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental:20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 four tablets (20mg) single oral dose at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:1mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:2mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:5mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo two tablets (10mg) single oral dose at Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:20mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC41 placebo four tablets (20mg) single oral dose at Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC41</intervention_name>
    <description>ASC41,1mg/table;5mg/table</description>
    <arm_group_label>Experimental:10mg</arm_group_label>
    <arm_group_label>Experimental:1mg</arm_group_label>
    <arm_group_label>Experimental:20mg</arm_group_label>
    <arm_group_label>Experimental:2mg</arm_group_label>
    <arm_group_label>Experimental:5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC41 placebo</intervention_name>
    <description>ASC41 placebo,1mg/table;5mg/table</description>
    <arm_group_label>Placebo:10mg</arm_group_label>
    <arm_group_label>Placebo:1mg</arm_group_label>
    <arm_group_label>Placebo:20mg</arm_group_label>
    <arm_group_label>Placebo:2mg</arm_group_label>
    <arm_group_label>Placebo:5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age 18-45 (including boundary value). 2. Male weight ≥ 50kg, female weight ≥&#xD;
             45kg;BMI ranges from 19 to 30kg/m2 (boundary value included).&#xD;
&#xD;
             3. She is of childbearing potential and is non-pregnant and willing to use adequate&#xD;
             contraception from screening (within 30days from the first administration)until one&#xD;
             month after the End of Study visit.&#xD;
&#xD;
             4. The pregnancy test of female subjects during the screening period is negative.&#xD;
&#xD;
             5. During the screening period, fasting low-density lipoprotein cholesterol (110mg/dl&#xD;
             &lt; fasting (LDL-C) &lt; 190mg/ dL.&#xD;
&#xD;
             6. Those who voluntarily sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with a history of thyroid disease or intolerance to beta blockers or&#xD;
             abnormal thyroid function indicators during screening; 2. Previous history of&#xD;
             fainting, fainting needle or fainting blood for unknown reasons.&#xD;
&#xD;
             3. Previous liver disease, or ALT, ASL and direct bilirubin in screening period exceed&#xD;
             the normal range.&#xD;
&#xD;
             4. Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), HIV&#xD;
             antibody (HIV Ab) and syphilis antibody are tested positive.&#xD;
&#xD;
             5. People who have taken special diet (including carambola, dragon fruit, mango,&#xD;
             grapefruit, orange, etc.) or drunk alcohol, or had strenuous exercise, or other&#xD;
             factors affecting drug absorption, distribution, metabolism, and excretion within 2&#xD;
             weeks before taking the study drug.&#xD;
&#xD;
             6. Heavy smokers (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL&#xD;
             spirits, or 100 mL wine;Smoking daily ≥ 5 sticks) and no smoking or alcohol&#xD;
             prohibition during the study period.&#xD;
&#xD;
             7. Ingesting chocolate, any food or drink containing caffeine or xanthine in the 24&#xD;
             hours prior to taking the study drug.&#xD;
&#xD;
             8. Patients who had donated blood or lost blood of more than 400ml within 3 months&#xD;
             before taking the study drug.&#xD;
&#xD;
             9. Those who have participated in other clinical trials and received study drug&#xD;
             treatment within 3 months before taking study drug.&#xD;
&#xD;
             10. In addition to the above, the researchers judge that the participants are not&#xD;
             suitable to participate in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hunan provincial people's hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

